SEC Form 4 · accession 0001209191-18-058718
ENDRA Life Sciences Inc. · NDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Digiandomenico
Director
Period of report
Nov 13, 2018
Accepted (ET)
Nov 15, 2018 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001681682
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 13, 2018 | C | 59,524 | $1.68 | A | 118,149 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Promissory NoteF2 | $1.68 | Nov 13, 2018 | C | — | D | — | Dec 31, 2018 | Common Stock | 59,524 | — | D |
Explanation of responses
- F1These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note described in footnote (2).
- F2Pursuant to the terms of the Convertible Promissory Note (the "Note"), the principal amount of the Note automatically converted into shares of the Issuer's Common Stock upon the consummation of a Qualified Financing (as defined in the Note) at the lowest per share price at which Common Stock was sold by the Issuer in the Qualified Financing, less a discount of 20%.